Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “TEVA PHARMACEUTICAL INDUSTRIES, LTD.”

302 pharma patents match "TEVA PHARMACEUTICAL INDUSTRIES, LTD." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 302
Index total 30,257
Page 6 / 13

Quick answer

This filtered view shows 302 pharmaceutical patents matching "TEVA PHARMACEUTICAL INDUSTRIES, LTD." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

302 results for “TEVA PHARMACEUTICAL INDUSTRIES, LTD.” · 30,257 patents in full index Clear search

  1. US 7871993

    Tigecycline crystalline forms and processes for preparation thereof

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Jan 18, 2011 · Expires Jan 13, 2031

    granted
  2. US 7868169

    Crystalline rosuvastatin intermediate

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Jan 11, 2011 · Expires Jan 6, 2031

    granted
  3. US 7855176

    Reduced volume formulation of glatiramer acetate and methods of administration

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Dec 21, 2010 · Expires Dec 16, 2030

    granted
  4. US 7855233

    Citrate salt of Rasagiline

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Dec 21, 2010 · Expires Dec 16, 2030

    granted
  5. US 7842717

    DNT-maleate and methods of preparation thereof

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Nov 30, 2010 · Expires Nov 25, 2030

    granted
  6. US 7815942

    Rasagiline formulations of improved content uniformity

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Oct 19, 2010 · Expires Oct 14, 2030

    granted
  7. US 7812168

    Purification of montelukast

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Oct 12, 2010 · Expires Oct 7, 2030

    granted
  8. US 7777034

    Crystalline ammonium salts of rosuvastatin

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Aug 17, 2010 · Expires Aug 12, 2030

    granted
  9. US 7759500

    2-(N-methyl-propanamine)-3-(2-naphthol)thiophene, an impurity of duloxetine hydrochloride

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Jul 20, 2010 · Expires Jul 15, 2030

    granted
  10. US 7750051

    Crystalline solid rasagiline base

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Jul 6, 2010 · Expires Jul 1, 2030

    granted
  11. US 7749536

    Pharmaceutical formulations of aliphatic amine polymers and methods for their manufacture

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Jul 6, 2010 · Expires Jul 1, 2030

    granted
  12. US 7741482

    Reference standard for characterization of rosuvastatin

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Jun 22, 2010 · Expires Jun 17, 2030

    granted
  13. US 7692009

    Reference standard for characterization of rosuvastatin

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Apr 6, 2010 · Expires Apr 1, 2030

    granted
  14. US 7692010

    Reference standard for characterization of rosuvastatin

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Apr 6, 2010 · Expires Apr 1, 2030

    granted
  15. US 7692008

    Reference standard for characterization of rosuvastatin

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Apr 6, 2010 · Expires Apr 1, 2030

    granted
  16. US 7687622

    Process for preparing quetiapine fumarate

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Mar 30, 2010 · Expires Mar 25, 2030

    granted
  17. US 7687642

    Fluvastatin sodium crystal forms, processes for preparing them, compositions containing them and methods of using them

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Mar 30, 2010 · Expires Mar 25, 2030

    granted
  18. US 7687660

    Process for preparing intermediates of HMG-CoA reductase inhibitors

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Mar 30, 2010 · Expires Mar 25, 2030

    granted
  19. US 7683080

    Stable iansoprazole containing more than 500 ppm, up to about 3,000 ppm water and more than 200 ppm, up to about 5,000 ppm alcohol

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Mar 23, 2010 · Expires Mar 18, 2030

    granted
  20. US 7683177

    Process for preparing 2-[(pyridinyl)methyl]sulfinyl-substituted benzimidazoles and novel chlorinated derivatives of pantoprazole

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Mar 23, 2010 · Expires Mar 18, 2030

    granted
  21. US 7678938

    Optical resolution of 3-carbamoylmethyl-5-methyl hexanoic acid

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Mar 16, 2010 · Expires Mar 11, 2030

    granted
  22. US 7678816

    Method of stabilizing lansoprazole

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Mar 16, 2010 · Expires Mar 11, 2030

    granted
  23. US 7678799

    Crystalline ziprasidone HCl and processes for preparation thereof

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Mar 16, 2010 · Expires Mar 11, 2030

    granted
  24. US 7674923

    Process for preparing forms of atorvastatin calcium substantially free of impurities

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Mar 9, 2010 · Expires Mar 4, 2030

    granted